Amica Mutual Insurance Co. lowered its stake in shares of Allergan plc (NYSE:AGN) by 40.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,608 shares of the company’s stock after selling 9,113 shares during the quarter. Amica Mutual Insurance Co.’s holdings in Allergan were worth $2,226,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in AGN. Quantitative Systematic Strategies LLC purchased a new position in Allergan in the third quarter worth $320,000. Assenagon Asset Management S.A. purchased a new position in Allergan in the third quarter worth $3,429,000. Fisher Asset Management LLC boosted its position in Allergan by 32.0% in the third quarter. Fisher Asset Management LLC now owns 7,015 shares of the company’s stock worth $1,438,000 after purchasing an additional 1,701 shares during the last quarter. Meeder Asset Management Inc. boosted its position in Allergan by 37.6% in the third quarter. Meeder Asset Management Inc. now owns 6,194 shares of the company’s stock worth $1,270,000 after purchasing an additional 1,693 shares during the last quarter. Finally, Rockefeller Financial Services Inc. boosted its position in Allergan by 283.7% in the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 79.66% of the company’s stock.
AGN has been the topic of several research analyst reports. Cantor Fitzgerald set a $191.00 price objective on Allergan and gave the stock a “hold” rating in a research report on Tuesday, December 12th. Vetr cut Allergan from a “hold” rating to a “sell” rating and set a $180.97 price objective on the stock. in a research report on Monday, January 22nd. Bank of America boosted their price objective on Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Deutsche Bank reissued a “buy” rating and issued a $215.00 price objective on shares of Allergan in a research report on Tuesday, January 9th. Finally, ValuEngine cut Allergan from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $227.23.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. The business had revenue of $4.33 billion for the quarter, compared to analysts’ expectations of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.90 EPS. analysts expect that Allergan plc will post 15.57 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This is a boost from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.81%. Allergan’s dividend payout ratio is -23.35%.
In other Allergan news, Director Chris W. Bodine bought 3,030 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were acquired at an average cost of $164.77 per share, for a total transaction of $499,253.10. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider William Meury sold 58,879 shares of the company’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total value of $9,457,144.98. The disclosure for this sale can be found here. Insiders have purchased a total of 17,630 shares of company stock worth $2,890,057 in the last three months. 0.36% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Amica Mutual Insurance Co. Sells 9,113 Shares of Allergan plc (AGN)” was reported by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://baseballnewssource.com/markets/amica-mutual-insurance-co-sells-9113-shares-of-allergan-plc-agn/1901215.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.